Cantor Fitzgerald raises Affirm stock price target to $80 on funding strength

Cantor Fitzgerald raised its price target on Affirm Holdings to $80 from $61 while keeping an Overweight rating, implying about 19% upside from the $67.06 share price. The firm argued that concerns about private credit redemptions and loan valuation risk are overblown, citing Affirm’s improving external funding track record and 32.7% revenue growth. The article also notes mixed peer analyst views, with targets ranging from $55 to $95.

Analysis

The key market implication is not that Affirm is “safe” from private-credit stress, but that its funding stack appears more diversified and more elastic than the market is pricing. In a stress window, lenders with documented access to multiple capital sources tend to gain share as weaker consumer finance platforms lose warehouse capacity or pay up sharply for term funding; that can actually widen Affirm’s relative moat even if sector headlines stay ugly for several weeks.

The second-order effect is on valuation dispersion inside fintech. If the market keeps conflating thematic fear around consumer credit with actual balance-sheet fragility, high-quality originators can rerate faster than the group, while lower-quality peers remain trapped at depressed multiples. That makes this a relative-value setup more than a clean directional one: the catalyst is not broad sector optimism, but the market’s recognition that funding risk and credit risk are being mispriced as the same thing.

The contrarian risk is that the current debate is too early to dismiss. Private credit redemptions can tighten liquidity conditions with a lag, and any rise in delinquencies or loss rates over the next 1-2 quarters would directly challenge the bull case. For AFRM, the stock can still work if fundamentals keep compounding, but the path likely remains volatile until the market gets one or two more quarters of clean credit data and stable external funding execution.

Key Decisions for Investors

• Long AFRM vs. a fintech basket short (e.g., equal-weight of higher-leverage consumer finance or BNPL peers) for a 3-6 month relative-value trade; thesis is dispersion widening as funding quality becomes the key differentiator.
• Buy AFRM on pullbacks toward the low-$60s with a 3-month horizon; upside is a re-rating toward the analyst cluster if funding concerns fade, while downside is capped by improving business momentum but remains vulnerable to credit prints.
• Use call spreads instead of outright long stock: AFRM 3-6 month call spreads to express upside from multiple expansion while limiting drawdown if private-credit headlines intensify.
• Pair long AFRM / short MS over 1-2 months only if you want to isolate the market’s misconception around consumer credit exposure; otherwise avoid the pair because MS is likely a low-beta hedge with limited catalyst rather than a true short.
• Trim or hedge if the next earnings cycle shows any deterioration in credit metrics; a single quarter of weaker loss trends would likely extend the de-rating by 15-25% before fundamentals reassert themselves.